GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Guardant Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$157.88−0.72 (-0.45%)
Close on Oct 19, 2026
- Market cap
- $20.98B
- P/E (TTM)
- –
- Dividend yield
- –
Guardant Health, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | $798.41M | $737.99M | $683.60M | $639.26M | $596.05M | $567.64M | $542.83M | – | – | – | – | – | 67.5% | +33.9% |
| Biopharma and data | $222.66M | $217.73M | $210.13M | $205.64M | $197.46M | $185.37M | $177.58M | – | – | – | – | – | 18.8% | +12.8% |
| Screening | $153.70M | $115.65M | $79.73M | $48.72M | $25.62M | $10.80M | $5.12M | – | – | – | – | – | 13.0% | +500.0% |
| Licensing and other | $8.34M | $8.85M | $8.56M | $8.95M | $9.73M | $10.19M | $13.49M | – | – | – | – | – | 0.7% | -14.3% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.12B | $1.01B | $923.28M | $851.33M | $781.99M | $733.42M | $697.16M | $648.18M | $603.81M | $564.96M | $526.52M | $501.72M | 94.3% | +42.7% |
| International | $67.45M | $65.92M | $58.74M | $51.24M | $46.86M | $40.57M | $41.85M | $44.07M | $40.00M | $38.76M | $37.42M | $34.06M | 5.7% | +44.0% |
From the segment and revenue-disaggregation notes of Guardant Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.